A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years

References

• Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001; 286:694 - 9; http://dx.doi.org/10.1001/jama.286.6.694; PMID: 11495619
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:Suppl 2 B51 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.04.063; PMID: 19477562
   PubMed Web of Science ®Google Scholar
• Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010; 9:285 - 98; http://dx.doi.org/10.1586/erv.10.3; PMID: 20218857
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological report. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm ECDC 2011; 155-57.
   Google Scholar
• Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27 - 36; http://dx.doi.org/10.1111/j.1574-6976.2006.00060.x; PMID: 17168995
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Surveillance of invasive disease in Europe 2008/09. Available at: http://ecdc.europa.eu/en/publications/Publications/1107_SUR_IBD_2008-09.pdf [Accessed 10/08/2012].
   Google Scholar
• Kriz P, Wieffer H, Holl K, Rosenlund M, Budhia S, Vyse A. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century. Expert Rev Vaccines 2011; 10:1477 - 86; http://dx.doi.org/10.1586/erv.11.117; PMID: 21988310
   PubMed Web of Science ®Google Scholar
• Thulin HS, Toros B, Fredlund H, Olcen P, Molling P. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011; 16
   Google Scholar
• Bidmos FA, Neal KR, Oldfield NJ, Turner DP, Ala’Aldeen DA, Bayliss CD. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011; 49:506 - 12; http://dx.doi.org/10.1128/JCM.01322-10; PMID: 21123536
   PubMed Web of Science ®Google Scholar
• The European Meningococcal Disease Society (EMGM). 11th EMGM meeting, May 18-20, 2011, Ljubljana, Slovenia. Emergence of serogroup Y: Poster abstracts P035-P40.
   Google Scholar
• Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23:Suppl S274 - 9; PMID: 15597069
   PubMedGoogle Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142 - 64; http://dx.doi.org/10.1128/CMR.19.1.142-164.2006; PMID: 16418528
   PubMed Web of Science ®Google Scholar
• Bröker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis 2010; 8:47 - 50; http://dx.doi.org/10.1016/j.tmaid.2009.12.001; PMID: 20188306
   PubMedGoogle Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737 - 43; http://dx.doi.org/10.1086/527401; PMID: 18271745
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Meningococcal conjugate vaccines. Expert Opin Biol Ther 2005; 5:1475 - 89; http://dx.doi.org/10.1517/14712598.5.11.1475; PMID: 16255651
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365 - 6; http://dx.doi.org/10.1136/bmj.326.7385.365; PMID: 12586669
   PubMed Web of Science ®Google Scholar
• Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines 2006; 5:851 - 7; http://dx.doi.org/10.1586/14760584.5.6.851; PMID: 17184222
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840 - 7; http://dx.doi.org/10.1128/CVI.00529-09; PMID: 20219881
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365 - 7; http://dx.doi.org/10.1016/S0140-6736(04)16725-1; PMID: 15276396
   PubMed Web of Science ®Google Scholar
• de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS ONE 2010; 5:e12144; http://dx.doi.org/10.1371/journal.pone.0012144; PMID: 20730091
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, García M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005; 23:4097 - 100; http://dx.doi.org/10.1016/j.vaccine.2005.03.045; PMID: 15908059
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907 - 13; http://dx.doi.org/10.1001/archpedi.159.10.907; PMID: 16203934
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al, V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:e1 - 10; http://dx.doi.org/10.1086/599117; PMID: 19476428
   PubMed Web of Science ®Google Scholar
• Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57 - 62; http://dx.doi.org/10.1097/01.inf.0000148928.10057.86; PMID: 15665711
   PubMed Web of Science ®Google Scholar
• Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.10.104; PMID: 19895922
   PubMed Web of Science ®Google Scholar
• Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009; 27:Suppl 2 B13 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.04.062; PMID: 19477559
   PubMed Web of Science ®Google Scholar
• Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009; 27:726 - 32; http://dx.doi.org/10.1016/j.vaccine.2008.11.065; PMID: 19063929
   PubMed Web of Science ®Google Scholar
• Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:2293 - 304; http://dx.doi.org/10.1056/NEJMoa1003812; PMID: 21675889
   PubMed Web of Science ®Google Scholar
• Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi M-P, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 25:Suppl 1 A101 - 7; http://dx.doi.org/10.1016/j.vaccine.2007.04.050; PMID: 17532101
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41 - 8; http://dx.doi.org/10.1097/INF.0b013e3182054ab9; PMID: 21200360
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239 - 47; http://dx.doi.org/10.4161/hv.7.2.14068; PMID: 21343698
   PubMed Web of Science ®Google Scholar
• Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744 - 53; http://dx.doi.org/10.1016/j.vaccine.2009.10.064; PMID: 19887137
   PubMed Web of Science ®Google Scholar
• Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56 - 62; http://dx.doi.org/10.1097/INF.0b013e31820e6e02; PMID: 21278617
   PubMed Web of Science ®Google Scholar
• Östergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161 - 8; http://dx.doi.org/10.1016/j.vaccine.2008.08.075; PMID: 18834910
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264 - 73; http://dx.doi.org/10.1016/j.vaccine.2011.03.009; PMID: 21420417
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274 - 84; http://dx.doi.org/10.1016/j.vaccine.2011.03.043; PMID: 21443965
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:RR-7 1 - 21; PMID: 15917737
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307 - 26; http://dx.doi.org/10.1084/jem.129.6.1307; PMID: 4977280
   PubMed Web of Science ®Google Scholar
• Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999; 18:641 - 6; http://dx.doi.org/10.1016/S0264-410X(99)00276-5; PMID: 10547423
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al, The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156 - 67; PMID: 9067649
   PubMedGoogle Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 2005; 23:2222 - 7; http://dx.doi.org/10.1016/j.vaccine.2005.01.051; PMID: 15755600
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine--United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1016 - 7; PMID: 16988640
   PubMedGoogle Scholar
• Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined?. Hum Vaccin 2008; 4:316 - 9; http://dx.doi.org/10.4161/hv.4.4.5751; PMID: 18398296
   PubMed Web of Science ®Google Scholar